The substitution of clotting factor products and the reduction of administered doses undertaken by the pharmacist have resulted in significant savings.

The current intervention demonstrated pharmacists can reduce clotting factor treatment costs by 20.5% (net savings of $12,000 for each treatment optimization).

Keywords: Hemophilia; Pharmacist; Prophylactic Treatment; Recombinant; Cost-Minimization